CommentN-acetylcysteine in COPD may be beneficial, but for whom?
References (16)
- et al.
N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease
COPD
(2006) - et al.
Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease
Int J Chron Obstruct Pulmon Dis
(2011) Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: National Clinical Guideline Centre
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease
- et al.
Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review
Pulm Pharmacol Ther
(2007) - et al.
High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study
Chest
(2013) - et al.
Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients
Int J Chron Obstruct Pulmon Dis
(2013) - et al.
Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial
Lancet Respir Med
(2014)
Cited by (15)
Stressed out - The role of oxidative stress in airway smooth muscle dysfunction in asthma and COPD
2022, Free Radical Biology and MedicineCitation Excerpt :A meta-analysis of 10 studies, plus a subsequent post-hoc analysis of the RESTORE study included in this meta-analysis, showed that erdosteine could reduce the rate of exacerbations, length of time to first COPD exacerbation, duration of exacerbation [217,218] as well as reducing the number of patients with at least one exacerbation and the risk of hospitalisation [217]. However in addition to their anti-oxidant activities thiol based anti-oxidants also have mucolytic activity and whether their effects are truly anti-oxidant or via their mucolytic activity remains unclear [219,220]. In addition, by virtue of being thiol-based these anti-oxidants can be inactivated by higher levels of ROS in the lungs which could limit their efficacy [220].
Optimal treatment sequence in COPD: Can a consensus be found?
2016, Revista Portuguesa de Pneumologia (English Edition)Citation Excerpt :High-dose NAC seems to decrease exacerbation frequency regardless of ICS therapy,47,49 but only in patients at high risk of exacerbations.50 This effect appears to be particularly evident in patients with moderate COPD,51 but limitations due to study population may preclude generalization of these conclusions.52,53 Low-dose NAC has no effect on exacerbation frequency49,54,55 or clinical outcomes.54,55
Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial
2015, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :Zheng et al. recently reported, a 22% relative reduction in AECOPD in patients treated with N-acetylcysteine compared with placebo, in the Chinese Pantheon trial, which they attributed to its antioxidant activity [26]. However, in a follow-up commentary in the same journal, Cazzola & Matera concluded that available evidence suggests that the effects of N-acetylcysteine on AECOPD were mainly related to its mucolytic action rather than to its antioxidant effects [27]. This opinion is strengthened by the fact that mucolytic drugs, irrespective of whether or not they are able to exert antioxidant effects, are associated with only a small reduction in AECOPD even at maximal dosages.
N-acetylcysteine for COPD: The evidence remains inconclusive
2014, The Lancet Respiratory MedicineA randomized, double-blind, placebo-controlled study evaluating the efficacy of propolis and N-acetylcysteine in exacerbations of chronic obstructive pulmonary disease
2022, European Review for Medical and Pharmacological SciencesPotential Mechanisms for Traditional Chinese Medicine in Treating Airway Mucus Hypersecretion Associated With Coronavirus Disease 2019
2020, Frontiers in Molecular Biosciences